Anthim
Active Ingredient(s): ObiltoxaximabFDA Approved: * March 18, 2016
Pharm Company: * ELUSYS THERAPEUTICS INC
Category: Antibiotics
Obiltoxaximab, sold under the brand name Anthim, is a monoclonal antibody medication designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).[3][1][4] The medication was developed by Elusys Therapeutics, Inc.[1][5] Contents 1 Medical uses 2 Society and culture 2.1 Legal status 3 References 4 External links Medical uses Obiltoxaximab is indicated in combination wit... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.